Business
Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021
IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Helio Health ("Helio"), an AI-driven healthcare company developing blood-based early
About this update from Fulgent Genetics, Inc.
[{"type":"text","content":" IRVINE, Calif. and TEMPLE CITY, Calif., Nov. 1, 2021 /PRNewswire/ -- Helio Health (\"Helio\"), an AI-driven healthcare company developing blood-based early cancer detection tests, and Fulgent Genetics, Inc. (NASDAQ: FLGT) (\"Fulgent\"), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced its upcoming late-breaking poster presentation on the performance of HelioLiver, a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers for the detection of hepatocellular carcinoma (HCC), at The Liver Meeting® 2021. The annual meeting is hosted by the American Association for the Study of Liver Diseases (AASLD) and will be held virtually November 12-15, 2021. \n\n \n \n \n \n \n \n\n \nDetails of the poster presentation are as follows:\nPoster Title: A Multi-Analyte Blood Test for Accurate and Early Detection of Hepatocellular Carcinoma Publication Number: LP44 Session Title: Late-breaking Abstract Posters Presenter: David J. Taggart, PhD, NRCC(CC) – Laboratory Director and Vice President of Laboratory Operations and Regulatory Affairs, Helio Health Inc. \nThe full abstract can be found here. The poster presentation will be available for viewing by the attendees of The Liver Meeting® throughout the entire meeting. \nAbout Helio Health\nHelio Health is an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw. The company's mission is to simplify cancer screening so lives can be saved by detecting cancer earlier. With Helio's AI-driven technology, both physicians and their patients gain powerful insights from accurate, accessible, and convenient blood tests.\nBuilding on a robust research and development program, and with access to thousands of patient samples, the company is currently in clinical trials in the US and China with its lead liver cancer detection test. Helio's development program is focused on liver, colon, breast and lung cancer.\nHelio Health is headquartered in Irvine, CA, with R&D, GMP and CLIA facilities in Irvine, CA and West Lafayette, IN, Guangzhou and Beijing.\nAbout Fulgent Genetics\nFulgent Genetics is a technology-based genetic testing company focused on transforming patient care in oncology, inf...